Abstract: Neoadjuvant endocrine therapy, a considerable treatment for hormone receptor-positive patients, can achieve the purpose of downsizing primary tumors and a high operability. This article consists of several parts: Selective patients, treatment duration, neoadjuvant chemotherapy vs. endocrine therapy, assessment of efficacy and possible predictive biomarkers etc. Results from present clinical trials will contribute to future investigation to establish the optimized treatments in individual patients.